Annals of Pharmacotherapy
Relacorilant in Combination With Nab-Paclitaxel for the Treatment of Adults With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Objective: To review the pharmacology, efficacy, and safety of relacorilant (Lifyorli) in combination with nab-paclitaxel (NP) for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy, including at least one bevacizumab-containing regimen. Data Sources: A literature search was conducted using Embase and PubMed/MEDLINE, applicable published abstracts, and ongoing studies from ClinicalTrials.gov betwee …